Let’s start up with the current stock price of Rubius Therapeutics Inc. (RUBY), which is $0.50 to be very precise. The Stock rose vividly during the last session to $0.51 after opening rate of $0.488 while the lowest price it went was recorded $0.4407 before closing at $0.45.Recently in News on September 19, 2022, Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference. Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT. You can read further details here
Rubius Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $10.4700 on 01/04/22, with the lowest value was $0.4407 for the same time period, recorded on 09/22/22.
Rubius Therapeutics Inc. (RUBY) full year performance was -97.65%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Rubius Therapeutics Inc. shares are logging -97.45% during the 52-week period from high price, and 14.00% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.44 and $19.70.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 18334751 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Rubius Therapeutics Inc. (RUBY) recorded performance in the market was -95.30%, having the revenues showcasing -54.54% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 49.85M, as it employees total of 213 workers.
The Analysts eye on Rubius Therapeutics Inc. (RUBY)
During the last month, 1 analysts gave the Rubius Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9085, with a change in the price was noted -1.23. In a similar fashion, Rubius Therapeutics Inc. posted a movement of -71.09% for the period of last 100 days, recording 2,505,899 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RUBY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.80.
Technical rundown of Rubius Therapeutics Inc. (RUBY)
Raw Stochastic average of Rubius Therapeutics Inc. in the period of last 50 days is set at 5.84%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 5.84%. In the last 20 days, the company’s Stochastic %K was 3.12% and its Stochastic %D was recorded 2.37%.
Considering, the past performance of Rubius Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -95.30%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -90.94%, alongside a downfall of -97.65% for the period of the last 12 months. The shares increased approximately by -34.26% in the 7-day charts and went up by -38.14% in the period of the last 30 days. Common stock shares were lifted by -54.54% during last recorded quarter.